Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-U00141 |
Brand: | MCE |
CAS: | 57818-44-7 |
MDL | - |
---|---|
Molecular Weight | 296.44 |
Molecular Formula | C18H32O3 |
SMILES | CCCCC/C=C\C/C=C\CCCCCCC(O)C(O)=O |
ABTL-0812 (ABTL0812; 10-100 μM; 48 hours) inhibits cell viability of squamous NSCLC H157 cells
[1]
.
Compared with squamous NSCLC H157 cells, human lung fibroblast cell line MRC-5 are resistant to ABTL0812 treatment
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
Cell Line: | Human lung fibroblast MRC5 and squamous non-small cell lung (NSCLC) H157 cells |
Concentration: | 10, 30, 100 μM |
Incubation Time: | 48 hours |
Result: | Inhibited cell viability of squamous NSCLC H157 cells, not lung fibroblast cell line MRC-5. |
ABTL-0812 (ABTL0812; 120 mg/kg; oral gavage; 5 times per week; for 33 d) induces ER stress in human lung and pancreatic xenografts
[1]
.
ABTL-0812 induces hallmarks of ER stress in vivo. ABTL-0812 increases ATF4 and HSPA5 expression in mice bearing MiaPaca2 and A549 xenograft, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Athymic female nude mice bearing MiaPaca2 and A549 xenograft models [1] |
Dosage: | 120 mg/kg |
Administration: | Administered by oral gavage; 5 times per week for 33 days |
Result: | Induced ER stress in human lung and pancreatic xenografts. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT03366480 | Ability Pharmaceuticals SL|Hospital Vall d´Hebron|Institut Català d´Oncologia|Hospital Clínico Universitario de Valencia|Hospitales Universitarios Virgen del Rocío|Centre Leon Berard|Institut Paoli-Calmettes|Gustave Roussy, Cancer Campus, Grand Paris |
Endometrial Cancer|Squamous Non-Small Cell Lung Cancer
|
December 1, 2016 | Phase 1|Phase 2 |
NCT04431258 | Ability Pharmaceuticals SL |
Pancreatic Cancer
|
May 6, 2021 | Phase 1|Phase 2 |
NCT02201823 | Ability Pharmaceuticals SL|Hospital Clinic of Barcelona|Institut Català d´Oncologia |
Cancer
|
February 2014 | Phase 1 |
NCT03417921 | Ability Pharmaceuticals SL|The Cleveland Clinic |
Pancreatic Cancer
|
December 1, 2020 | Phase 1|Phase 2 |
Liquid
Room temperature in continental US; may vary elsewhere.
Pure form | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 250 mg/mL ( 843.34 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.3734 mL | 16.8668 mL | 33.7336 mL |
5 mM | 0.6747 mL | 3.3734 mL | 6.7467 mL |
10 mM | 0.3373 mL | 1.6867 mL | 3.3734 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.